<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 27 Mar 2025 20:12:25 +0000</lastbuilddate>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40140695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 26. doi: 10.1038/s41569-025-01149-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40140695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40140695</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01149-8>10.1038/s41569-025-01149-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40140695</guid>
<pubDate>Thu, 27 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-03-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling</dc:title>
<dc:identifier>pmid:40140695</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01149-8</dc:identifier>
</item>
<item>
<title>Ventricular Wall Stress in Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):e133. doi: 10.1016/j.jacc.2024.08.091.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139898</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.091>10.1016/j.jacc.2024.08.091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139898</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kazuo Komamura</dc:creator>
<dc:creator>Hiroshi Miyake</dc:creator>
<dc:creator>Koichi Kobayashi</dc:creator>
<dc:creator>Ryoji Ishiki</dc:creator>
<dc:creator>Mitsunori Iwase</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Wall Stress in Aortic Stenosis</dc:title>
<dc:identifier>pmid:40139898</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.091</dc:identifier>
</item>
<item>
<title>Reply: Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):e131. doi: 10.1016/j.jacc.2025.01.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139897</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.023>10.1016/j.jacc.2025.01.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139897</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lisa E Vaughan</dc:creator>
<dc:creator>Vesna D Garovic</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:40139897</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.023</dc:identifier>
</item>
<item>
<title>Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):e129-e130. doi: 10.1016/j.jacc.2024.11.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139896</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.053>10.1016/j.jacc.2024.11.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139896</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ruyi Zhou</dc:creator>
<dc:creator>Senlin Ye</dc:creator>
<dc:creator>Jinli Liu</dc:creator>
<dc:creator>Lincheng Duan</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Social Work Interventions to Reduce Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:40139896</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.053</dc:identifier>
</item>
<item>
<title>Using Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139895/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1376-1378. doi: 10.1016/j.jacc.2025.01.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139895/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139895</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.005>10.1016/j.jacc.2025.01.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139895</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>George Goshua</dc:creator>
<dc:creator>Merilyn Varghese</dc:creator>
<dc:creator>Satoko Ito</dc:creator>
<dc:creator>Ankur Pandya</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Distributional Cost-Effectiveness Analysis to Improve Equity and Efficiency</dc:title>
<dc:identifier>pmid:40139895</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.005</dc:identifier>
</item>
<item>
<title>Albuminuria: A Marker of Adverse Kidney Outcomes in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139894/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1372-1375. doi: 10.1016/j.jacc.2025.01.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139894/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139894</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.025>10.1016/j.jacc.2025.01.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139894</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sophie E Claudel</dc:creator>
<dc:creator>Insa M Schmidt</dc:creator>
<dc:creator>Sushrut S Waikar</dc:creator>
<dc:creator>Ashish Verma</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Albuminuria: A Marker of Adverse Kidney Outcomes in Heart Failure</dc:title>
<dc:identifier>pmid:40139894</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.025</dc:identifier>
</item>
<item>
<title>The Importance of Remnant Cholesterol in PAD: Hidden in Plain Sight</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139893/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1369-1371. doi: 10.1016/j.jacc.2025.01.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139893/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139893</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.027>10.1016/j.jacc.2025.01.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139893</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Importance of Remnant Cholesterol in PAD: Hidden in Plain Sight</dc:title>
<dc:identifier>pmid:40139893</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.027</dc:identifier>
</item>
<item>
<title>Elevated Remnant and LDL Cholesterol and the Risk of Peripheral Artery Disease: A Mendelian Randomization Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139892/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Elevated remnant cholesterol had a causal effect on risk of PAD even after accounting for elevated LDL cholesterol, whereas most of the causal effect of elevated LDL cholesterol on risk of PAD was dependent on simultaneously elevated remnant cholesterol. These results indicate that remnant cholesterol may be the major cholesterol fraction responsible for increased risk of PAD. Future studies should investigate the biological mechanisms behind these findings to find improved...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1353-1368. doi: 10.1016/j.jacc.2024.12.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Elevated remnant cholesterol and low-density lipoprotein (LDL) cholesterol both increase the risk of coronary artery disease (CAD), but it is not known if the same is true for peripheral artery disease (PAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study tested the hypothesis that elevated remnant cholesterol and LDL cholesterol, each independent of the other, have causal effects on risk of PAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors constructed genetic scores from variants near genes known to directly affect levels of remnant cholesterol and LDL cholesterol, identified through a genome-wide association study of individuals in the UK Biobank. Univariable (remnant cholesterol and LDL cholesterol genetic scores separately) and multivariable (remnant cholesterol and LDL cholesterol genetic scores combined) Mendelian randomization were used to estimate the causal effects of higher remnant cholesterol and LDL cholesterol levels on ORs for PAD (n = 38,414 cases and 758,308 controls) and CAD (n = 221,445 cases and 770,615 controls).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Increments in remnant and LDL genetic scores corresponding to 1 mmol/L (39 mg/dL) higher remnant and LDL cholesterol, respectively, were associated with univariable ORs for PAD of 2.72 (95% CI: 2.10-3.52) and 1.37 (95% CI: 1.25-1.51); corresponding multivariable ORs were 2.16 (95% CI: 1.49-3.12) and 1.14 (95% CI: 1.00-1.30). For CAD, corresponding univariable ORs were 2.92 (95% CI: 2.34-3.64) and 1.67 (95% CI: 1.56-1.79), whereas multivariable ORs were 1.86 (95% CI: 1.39-2.47) and 1.44 (95% CI: 1.29-1.60). Scaled to 1 SD increments in remnant cholesterol and LDL cholesterol, corresponding univariable ORs were 1.37 (95% CI: 1.27-1.49) and 1.29 (95% CI: 1.20-1.39) for PAD, and 1.40 (95% CI: 1.31-1.51) and 1.51 (95% CI: 1.43-1.59) for CAD; corresponding multivariable ORs were 1.28 (95% CI: 1.14-1.43) and 1.11 (95% CI: 1.00-1.23) for PAD, and 1.22 (95% CI: 1.11-1.33) and 1.34 (95% CI: 1.23-1.46) for CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Elevated remnant cholesterol had a causal effect on risk of PAD even after accounting for elevated LDL cholesterol, whereas most of the causal effect of elevated LDL cholesterol on risk of PAD was dependent on simultaneously elevated remnant cholesterol. These results indicate that remnant cholesterol may be the major cholesterol fraction responsible for increased risk of PAD. Future studies should investigate the biological mechanisms behind these findings to find improved therapies for prevention and treatment of PAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139892/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139892</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.033>10.1016/j.jacc.2024.12.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139892</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Benjamin Nilsson Wadström</dc:creator>
<dc:creator>Maria Carolina Borges</dc:creator>
<dc:creator>Anders Berg Wulff</dc:creator>
<dc:creator>George Davey Smith</dc:creator>
<dc:creator>Eleanor Sanderson</dc:creator>
<dc:creator>Børge Grønne Nordestgaard</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Elevated Remnant and LDL Cholesterol and the Risk of Peripheral Artery Disease: A Mendelian Randomization Study</dc:title>
<dc:identifier>pmid:40139892</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.033</dc:identifier>
</item>
<item>
<title>Evidence of Benefit for Chronic Total Occlusion Revascularization From ISCHEMIA: New Road or Dead End?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1350-1352. doi: 10.1016/j.jacc.2025.02.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139891</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.011>10.1016/j.jacc.2025.02.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139891</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ziad A Ali</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>John A Bittl</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evidence of Benefit for Chronic Total Occlusion Revascularization From ISCHEMIA: New Road or Dead End?</dc:title>
<dc:identifier>pmid:40139891</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.011</dc:identifier>
</item>
<item>
<title>Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the ISCHEMIA trial, the risks and benefits of INV compared with CON were similar among patients with and without CCTA-determined CTO (more frequent procedural MI, less frequent spontaneous MI, and significantly improved angina and dyspnea-related quality of life). In an observational comparison, successful CTO REV was associated with a high probability of lower CV death or MI (driven by lower MI) compared with CON. (International Study of Comparative Health Effectiveness With...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1335-1349. doi: 10.1016/j.jacc.2025.01.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Randomized trials of chronic total occlusion (CTO) revascularization vs medical therapy have yielded inconsistent results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate outcomes with an initial invasive strategy (INV) vs an initial conservative strategy (CON) in patients with coronary computed tomographic angiography (CCTA)-determined CTO in the ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants in ISCHEMIA who underwent CCTA evaluated for CTO by the core laboratory (3,113 of 5,179 randomized patients [60%]) were categorized into subgroups with (100% stenosis) and without (&lt;100% stenosis) CTO. Primary analysis compared outcomes in those randomized to INV vs CON using an intention-to-treat approach. Secondary analyses compared outcomes using inverse probability weighting to model successful CTO revascularization (REV) in all INV participants vs CON participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 3,113 CCTA-evaluable participants, 1,470 had at least 1 CTO (752 INV and 718 CON). INV did not reduce cardiovascular (CV) death or myocardial infarction (MI) (5-year difference -3.5%; 95% CI: -7.8% to 0.8%) and resulted in more procedural MIs (2.5%; 95% CI: 1.0%-4.0%) but fewer spontaneous MIs (-6.3%; 95% CI: -9.7% to -3.2%) than CON. CTO REV modeled across INV had a high probability (>;90%) of any lower CV death or MI, MI, spontaneous MI, unstable angina, and heart failure counterbalanced by a higher rate of procedural MI. CTO REV significantly improved angina-related quality of life (mean difference 4.6 points), Rose Dyspnea Scale score (rescaled) (mean difference 5.3 points), and EQ-5D visual analog scale score (4.6 points).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the ISCHEMIA trial, the risks and benefits of INV compared with CON were similar among patients with and without CCTA-determined CTO (more frequent procedural MI, less frequent spontaneous MI, and significantly improved angina and dyspnea-related quality of life). In an observational comparison, successful CTO REV was associated with a high probability of lower CV death or MI (driven by lower MI) compared with CON. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139890</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.029>10.1016/j.jacc.2025.01.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139890</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>G B John Mancini</dc:creator>
<dc:creator>Jonathan Leipsic</dc:creator>
<dc:creator>Mathew J Budoff</dc:creator>
<dc:creator>Yifan Xu</dc:creator>
<dc:creator>Rebecca Anthopolos</dc:creator>
<dc:creator>Emmanouil S Brilakis</dc:creator>
<dc:creator>Aeshita Dwivedi</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Phil G Jones</dc:creator>
<dc:creator>Yoon Joo Cho</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Cameron J Hague</dc:creator>
<dc:creator>James K Min</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Ahmed Elghamaz</dc:creator>
<dc:creator>Rajesh Goplan Nair</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Gilbert Gosselin</dc:creator>
<dc:creator>Subhash Banerjee</dc:creator>
<dc:creator>Hristo Pejkov</dc:creator>
<dc:creator>Steven Lindsay</dc:creator>
<dc:creator>J Aaron Grantham</dc:creator>
<dc:creator>David O Williams</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Sean M O'Brien</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:40139890</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.029</dc:identifier>
</item>
<item>
<title>Using Joint Models to Find What Worked Best in ISCHEMIA: Setting a New Standard</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139889/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1332-1334. doi: 10.1016/j.jacc.2025.02.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139889/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139889</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.003>10.1016/j.jacc.2025.02.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139889</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>John A Bittl</dc:creator>
<dc:creator>Haiqun Lin</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Joint Models to Find What Worked Best in ISCHEMIA: Setting a New Standard</dc:title>
<dc:identifier>pmid:40139889</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.003</dc:identifier>
</item>
<item>
<title>Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1317-1331. doi: 10.1016/j.jacc.2025.01.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Guideline-directed medical therapy (GDMT) with multiple risk factor goals is recommended for patients with chronic coronary disease (CCD), yet achieving all GDMT goals is uncommon. The relative importance of these goals and timing of their attainment on cardiovascular events is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to describe the relationship between achieving specific GDMT goals, when they are achieved, and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was an observational study of participants with CCD in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial. The primary outcome was cardiovascular (CV) death or myocardial infarction (MI). GDMT goals were systolic blood pressure (SBP) &lt;130 mm Hg, low-density lipoprotein cholesterol &lt;70 mg/dL, not smoking, and antiplatelet therapy. Frequency of GDMT goals met at baseline and during follow-up is described. Bayesian joint modeling for longitudinal goal status and time-to-event analyses characterized the relative importance of specific GDMT goal attainment and timing with CV death/MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: All 5,179 ISCHEMIA participants were included. Among 4,914 participants with complete data on all 4 GDMT goals at baseline, 386 (9%), 2,073 (42%), 1,843 (38%), and 612 (12%) met 0-1, 2, 3, and 4 GDMT goals, respectively. The 4-year cumulative event rate for CV death/MI was highest for participants who attained no GDMT goals (24.5%; 95% credible interval [CrI]: 13.5%-42.2%) and lowest for those who attained all goals at baseline and remained at goal during follow-up (8.7%; 95% CrI: 6.7%-10.9%). SBP goal attainment was associated with a significant absolute event reduction in CV death/MI (-5.1%; 95% CrI: -11.3% to -1.0%), followed by antiplatelet therapy (-11.2%; 95% CrI: -29.1% to 0.8%), achieving low-density lipoprotein cholesterol &lt;70 mg/dL (-2.0%; 95% CrI: -6.0% to 2.4%), and not smoking (-1.7%; 95% CrI: -9.3% to 4.2%). Ten millimeters of mercury lower SBP during follow-up was associated with 10% relative risk reduction of CV death/MI (RR [relative risk] = 0.90; 95% CrI: 0.82-0.98), after adjusting for other GDMT goals and baseline characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139888</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.028>10.1016/j.jacc.2025.01.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139888</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Jonathan D Newman</dc:creator>
<dc:creator>Rebecca Anthopolos</dc:creator>
<dc:creator>Ying Lu</dc:creator>
<dc:creator>Susanna Stevens</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Jason Linefsky</dc:creator>
<dc:creator>Rajesh G Nair</dc:creator>
<dc:creator>Olga Bockeria</dc:creator>
<dc:creator>Gilbert Gosselin</dc:creator>
<dc:creator>Gian P Perna</dc:creator>
<dc:creator>Elena Demchenko</dc:creator>
<dc:creator>David Foo</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>Mary Ann Champagne</dc:creator>
<dc:creator>Christie Ballantyne</dc:creator>
<dc:creator>Peter McCullough</dc:creator>
<dc:creator>Jose Luis Lopez-Sendon</dc:creator>
<dc:creator>Frank Rockhold</dc:creator>
<dc:creator>Frank Harrell</dc:creator>
<dc:creator>Yves Rosenberg</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:40139888</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.028</dc:identifier>
</item>
<item>
<title>Implementing ECG-AI in Clinical Care: From Pixel to Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1314-1316. doi: 10.1016/j.jacc.2025.02.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139887</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.008>10.1016/j.jacc.2025.02.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139887</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Minjae Yoon</dc:creator>
<dc:creator>Seng Chan You</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implementing ECG-AI in Clinical Care: From Pixel to Practice</dc:title>
<dc:identifier>pmid:40139887</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.008</dc:identifier>
</item>
<item>
<title>Ensemble Deep Learning Algorithm for Structural Heart Disease Screening Using Electrocardiographic Images: PRESENT SHD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We developed and validated PRESENT-SHD, an AI-ECG tool identifying a range of SHD using images of 12-lead ECGs, representing a robust, scalable, and accessible modality for automated SHD screening and risk stratification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1302-1313. doi: 10.1016/j.jacc.2025.01.030.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Identifying structural heart diseases (SHDs) early can change the course of the disease, but their diagnosis requires cardiac imaging, which is limited in accessibility.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to leverage images of 12-lead electrocardiograms (ECGs) for automated detection and prediction of multiple SHDs using an ensemble deep learning approach.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We developed a series of convolutional neural network models for detecting a range of individual SHDs from images of ECGs with SHDs defined by transthoracic echocardiograms performed within 30 days of the ECG at the Yale New Haven Hospital (YNHH). SHDs were defined as left ventricular ejection fraction &lt;40%, moderate-to-severe left-sided valvular disease (aortic/mitral stenosis or regurgitation), or severe left ventricular hypertrophy (interventricular septal diameter at end-diastole >;1.5 cm and diastolic dysfunction). We developed an ensemble XGBoost model, PRESENT-SHD (Practical scREening using ENsemble machine learning sTrategy for SHD detection), as a composite screen across all SHDs. We validated PRESENT-SHD at 4 U.S. hospitals and the prospective, population-based ELSA-Brasil (Brazilian Longitudinal Study of Adult Health) cohort, with concurrent protocolized ECGs and transthoracic echocardiograms. We also used PRESENT-SHD for risk stratification of new-onset SHD or heart failure (HF) in clinical cohorts and the population-based UK Biobank.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The models were developed using 261,228 ECGs from 93,693 YNHH patients and evaluated on a single ECG from 11,023 individuals at YNHH (19% with SHD), 44,591 across external hospitals (20%-27% with SHD), and 3,014 in the ELSA-Brasil (3% with SHD). In the held-out test set, PRESENT-SHD demonstrated an area under the receiver-operating characteristic curve (AUROC) of 0.886 (95% CI: 0.877-894), 90% sensitivity, and 66% specificity. At hospital-based sites, PRESENT-SHD had AUROCs ranging from 0.854 to 0.900, with sensitivities and specificities of 93% to 96% and 51% to 56%, respectively. The model generalized well to ELSA-Brasil (AUROC 0.853 [95% CI: 0.811-0.897], 88% sensitivity, 62% specificity). PRESENT-SHD demonstrated consistent performance across demographic subgroups, novel ECG formats, and smartphone photographs of ECGs from monitors and printouts. A positive PRESENT-SHD screen portended a 2- to 4-fold higher risk of new-onset SHD/heart failure, independent of demographics, comorbidities, and the competing risk of death across clinical sites and UK Biobank, with high predictive discrimination.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We developed and validated PRESENT-SHD, an AI-ECG tool identifying a range of SHD using images of 12-lead ECGs, representing a robust, scalable, and accessible modality for automated SHD screening and risk stratification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139886</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.030>10.1016/j.jacc.2025.01.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139886</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lovedeep S Dhingra</dc:creator>
<dc:creator>Arya Aminorroaya</dc:creator>
<dc:creator>Veer Sangha</dc:creator>
<dc:creator>Aline F Pedroso</dc:creator>
<dc:creator>Sumukh Vasisht Shankar</dc:creator>
<dc:creator>Andreas Coppi</dc:creator>
<dc:creator>Murilo Foppa</dc:creator>
<dc:creator>Luisa C C Brant</dc:creator>
<dc:creator>Sandhi M Barreto</dc:creator>
<dc:creator>Antonio Luiz P Ribeiro</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ensemble Deep Learning Algorithm for Structural Heart Disease Screening Using Electrocardiographic Images: PRESENT SHD</dc:title>
<dc:identifier>pmid:40139886</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.030</dc:identifier>
</item>
<item>
<title>Revisiting Mechanical Aortic Valves in Younger Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1299-1301. doi: 10.1016/j.jacc.2025.02.021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139885</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.021>10.1016/j.jacc.2025.02.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139885</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Makoto Mori</dc:creator>
<dc:creator>Arnar Geirsson</dc:creator>
<dc:creator>Isaac George</dc:creator>
<dc:creator>Mark J Russo</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Revisiting Mechanical Aortic Valves in Younger Patients</dc:title>
<dc:identifier>pmid:40139885</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.021</dc:identifier>
</item>
<item>
<title>Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40 to 75 Years of Age</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40139884/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients aged ≤60 years, mechanical AVR was associated with an independent risk-adjusted survival benefit compared with bioprosthetic AVR. These contemporary 12-year survival data further inform patient and provider shared clinical decision-making regarding prosthetic aortic valves.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Apr 1;85(12):1289-1298. doi: 10.1016/j.jacc.2025.01.013. Epub 2025 Jan 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The choice of bioprosthetic or mechanical surgical aortic valve replacement (AVR) should balance individual valve durability with the potential liabilities of oral anticoagulation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To inform clinical practice, this study sought to evaluate contemporary, real-world, long-term AVR outcomes from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS ACSD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All patients undergoing primary isolated bioprosthetic or mechanical AVR were identified. Patients aged &lt;40 and >;75 years with endocarditis, emergency/salvage status, shock, ejection fraction ≤25%, and any prior cardiac surgery were excluded. Validated methodology was applied for linkage to the National Death Index to define longitudinal all-cause mortality (2008-2019). Robust risk adjustment was performed by using age-specific inverse probability weighting and restricted cubic splines to model nonlinear age relationships. Sensitivity analyses excluded pure aortic insufficiency, intermediate/high risk (STS predicted risk of operative mortality >;4%), and discontinued valve types.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 109,842 patients underwent bioprosthetic (n = 94,125) or mechanical (n = 15,717) AVR during the study period. After risk adjustment, freedom from all-cause mortality favored mechanical valves in patients aged 60 years and younger. Age group-specific analyses showed that mechanical valves were associated with lower all-cause mortality in all age groups ≤60 years. These results remained consistent across all sensitivity analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients aged ≤60 years, mechanical AVR was associated with an independent risk-adjusted survival benefit compared with bioprosthetic AVR. These contemporary 12-year survival data further inform patient and provider shared clinical decision-making regarding prosthetic aortic valves.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40139884/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40139884</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.013>10.1016/j.jacc.2025.01.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40139884</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael E Bowdish</dc:creator>
<dc:creator>J Hunter Mehaffey</dc:creator>
<dc:creator>Shu-Ching Chang</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Andrew B Goldstone</dc:creator>
<dc:creator>Joanna Chikwe</dc:creator>
<dc:creator>A Marc Gillinov</dc:creator>
<dc:creator>Changfu Wu</dc:creator>
<dc:creator>Gregory P Fontana</dc:creator>
<dc:creator>Joseph E Bavaria</dc:creator>
<dc:creator>Chris S Malaisrie</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Ibrahim S Sultan</dc:creator>
<dc:creator>Moritz C Wyler von Ballmoos</dc:creator>
<dc:creator>Kathrine B Harrington</dc:creator>
<dc:creator>Jeffrey P Jacobs</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Wilson Y Szeto</dc:creator>
<dc:creator>Joseph F Sabik</dc:creator>
<dc:creator>Robert H Habib</dc:creator>
<dc:creator>Vinay Badhwar</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40 to 75 Years of Age</dc:title>
<dc:identifier>pmid:40139884</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.013</dc:identifier>
</item>
<item>
<title>Aortic Valve Intervention for Asymptomatic Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40136312/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0483. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40136312/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40136312</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0483>10.1001/jamacardio.2025.0483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40136312</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Rick A Nishimura</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aortic Valve Intervention for Asymptomatic Aortic Stenosis</dc:title>
<dc:identifier>pmid:40136312</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0483</dc:identifier>
</item>
<item>
<title>Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40136309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the OCEANIC-AF randomized clinical trial, patients with AF who were OAC naive had a smaller increase in stroke or systemic embolism and a similar lower rate of bleeding with asundexian compared with apixaban than patients who were OAC experienced. The mechanism of these findings is unknown and deserves further research.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0277. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In patients with atrial fibrillation (AF), oral anticoagulants (OACs) reduce the risk of stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate if patients with less prior OAC exposure respond differently to a new OAC than patients with more OAC exposure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this prespecified exploratory subgroup analysis of the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic-Atrial Fibrillation (OCEANIC-AF) randomized clinical trial, patients enrolled in the OCEANIC-AF trial were categorized as OAC naive or OAC experienced based on whether they had 6 or fewer weeks or more than 6 weeks of prior OAC use. The effect of asundexian vs apixaban was then compared on outcomes among patients who were OAC naive and OAC experienced. The study setting included 1035 sites in 38 countries, and participants were those enrolled in the OCEANIC-AF trial. Data were analyzed from June to July 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Asundexian, a novel factor XIa inhibitor, was compared with apixaban in patients with AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was stroke or systemic embolism. The main safety outcome was major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of patients in the OCEANIC-AF trial, 2493 (17%) were OAC naive (mean [SD] age, 72.6 [8.6] years; 1464 male [59%]) and 12 317 (83%) were OAC experienced (mean [SD] age, 74.2 [7.5] years; 8132 male [66%]). In the asundexian arm, patients who were OAC naive had a stroke or systemic embolism rate of 0.8% (10 of 1238) compared with 1.4% (88 of 6177) in those who were OAC experienced. In the apixaban arm, patients who were OAC naive had a stroke or systemic embolism rate of 0.6% (7 of 1255) compared with 0.3% (19 of 6140) in those who were OAC experienced. Thus, patients who were OAC naive had a smaller increase in stroke or systemic embolism with asundexian compared with apixaban (hazard ratio [HR], 1.42; 95% CI, 0.54-3.73) than patients who were OAC experienced (HR, 4.66; 95% CI, 2.84-7.65; P for interaction =.03). Bleeding rates were lower among both OAC-naive patients (0.2% [2 of 1228]) and OAC-experienced patients (0.2% [15 of 6145]) assigned asundexian than among OAC-naive patients (1.0% [13 of 1249]) and OAC-experienced patients (0.7% [40 of 6115]) assigned apixaban.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the OCEANIC-AF randomized clinical trial, patients with AF who were OAC naive had a smaller increase in stroke or systemic embolism and a similar lower rate of bleeding with asundexian compared with apixaban than patients who were OAC experienced. The mechanism of these findings is unknown and deserves further research.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05643573.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40136309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40136309</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0277>10.1001/jamacardio.2025.0277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40136309</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Elizabeth J Lydon</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Thomas Viethen</dc:creator>
<dc:creator>Jonas Oldgren</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Jan Steffel</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Isabelle C van Gelder</dc:creator>
<dc:creator>Keith C Ferdinand</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Hardi Mundl</dc:creator>
<dc:creator>Bela Benczur</dc:creator>
<dc:creator>Juan José Gómez-Doblas</dc:creator>
<dc:creator>Michael Glikson</dc:creator>
<dc:creator>Assen Goudev</dc:creator>
<dc:creator>Erik L Grove</dc:creator>
<dc:creator>Sigrun Halvorsen</dc:creator>
<dc:creator>Tuomas Kiviniemi</dc:creator>
<dc:creator>Anne-Céline Martin</dc:creator>
<dc:creator>Roopinder K Sandhu</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Frank W Rockhold</dc:creator>
<dc:creator>Valeria Caso</dc:creator>
<dc:creator>Rosa Coppolecchia</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40136309</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0277</dc:identifier>
</item>
<item>
<title>Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40136263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In these 2 cluster randomized clinical trials, visit-based interruptive alerts were not associated with a significant increase in statin prescribing compared with usual care, whereas a strategy of asynchronous semiautomated referral for pharmacist comanagement was associated with a substantial increase. This strategy of asynchronous semiautomated referrals for pharmacist involvement in lipid management could be a scalable and effective approach to increasing statin...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 26. doi: 10.1001/jamacardio.2025.0244. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Despite statins' benefit in preventing major adverse cardiovascular events, most patients with an indication for statin therapy are not appropriately treated. Clinicians' limited time and lack of systematic efforts to address preventive care likely contribute to gaps in statin prescribing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the effect on statin prescribing of 2 interventions to refer appropriate patients to a pharmacist for lipid management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: These 2 pragmatic cluster randomized clinical trials were conducted among 12 total primary care practices in a community health system. Trial 1 was a delayed-intervention design of a visit-based intervention with randomization at the clinician level in a single clinic, and trial 2 was a parallel-arm trial of an asynchronous intervention with randomization at the clinic level in 11 clinics. Patients who were assigned to a primary care clinician at a participating practice, had an indication for a high-intensity or moderate-intensity statin, and were either not prescribed a statin or prescribed an inappropriately low statin dose were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Trial 1 tested an interruptive electronic health record alert that appeared during eligible patients' visits and facilitated referral to a pharmacist, while trial 2 tested an order for pharmacist referral placed by the study team for cosignature by the primary care clinician without regard to the timing of a clinic visit.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURE: The primary outcome was the proportion of patients prescribed a statin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 1412 patients were enrolled in trial 1 and 1950 in trial 2. Across both trials, mean (SD) patient age was 65.6 (9.9) years, and 1485 patients (44.2%) were female. Mean (SD) baseline 10-year risk of major cardiovascular events was 17.9% (9.4). In trial 1, the interruptive alert was not associated with a significant increase in statin prescriptions compared with usual care (15.6% vs 11.6%; unadjusted absolute difference, 3.9 percentage points; 95% CI, -0.4 to 8.3). In trial 2, semiautomated pharmacist referrals were associated with an increase in statin prescriptions by 16 percentage points compared with usual care (31.6% vs 15.2%; unadjusted absolute difference, 16.4 percentage points; 95% CI, 12.7-20.1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In these 2 cluster randomized clinical trials, visit-based interruptive alerts were not associated with a significant increase in statin prescribing compared with usual care, whereas a strategy of asynchronous semiautomated referral for pharmacist comanagement was associated with a substantial increase. This strategy of asynchronous semiautomated referrals for pharmacist involvement in lipid management could be a scalable and effective approach to increasing statin prescribing for patients at high risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05537064.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40136263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40136263</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0244>10.1001/jamacardio.2025.0244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40136263</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Qian Huang</dc:creator>
<dc:creator>Kayla Clark</dc:creator>
<dc:creator>Laurie A Norton</dc:creator>
<dc:creator>Wendell E Kellum</dc:creator>
<dc:creator>Dwight Eichelberger</dc:creator>
<dc:creator>John C Wood</dc:creator>
<dc:creator>Zachary Bricker</dc:creator>
<dc:creator>Andrea G Dooley Wood</dc:creator>
<dc:creator>Greta Kemmer</dc:creator>
<dc:creator>Jennifer I Smith</dc:creator>
<dc:creator>Srinath Adusumalli</dc:creator>
<dc:creator>Mary E Putt</dc:creator>
<dc:creator>Kevin G Volpp</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:40136263</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0244</dc:identifier>
</item>
<item>
<title>MAIT Cells Promote Cholesterol Excretion Pathways Mitigating Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40135347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings demonstrate a new mechanism for plasma VLDL-C clearance by MAIT cell-mediated cholesterol excretion. The results provide further evidence that immunity is involved in cholesterol homeostasis. Targeting intestinal immunity to regulate cholesterol homeostasis holds promise as a new cholesterol-lowering modality to prevent atherosclerotic cardiovascular disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 26. doi: 10.1161/CIRCRESAHA.124.325841. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Previous clinical studies have indicated reduced circulating mucosal-associated invariant T (MAIT) cells in individuals with coronary artery disease. However, the precise role and underlying mechanisms of MAIT cells in this context remain unclear. Immune homeostasis plays a pivotal role in the development of atherosclerosis. This study explores the impact of MAIT cells on atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Vα19<sup>+/-</sup> Ldlr<sup>-/-</sup> mice, characterized by a high MAIT cell frequency, and MAIT cell deficient MR1<sup>-/-</sup> (major histocompatibility complex-related molecule 1) Ldlr<sup>-/-</sup> mice and their respective controls were used. Starting at 6 weeks of age, mice were subjected to a 1% cholesterol diet for 16 weeks. Additionally, the study analyzed circulating MAIT cell frequency and cholesterol levels in 68 patients with hypercholesterolemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In Vα19<sup>+/-</sup> Ldlr<sup>-/-</sup> mice, increased MAIT cells demonstrated a protective effect against atherosclerosis by reducing VLDL-C (very-low-density lipoprotein cholesterol) levels through heightened cholesterol excretion. This effect was accompanied by elevated jejunal ABCB1a, ABCG5, and ABCG8 expression, mediated by augmented levels of LXR transcription and activation, likely through intestinal IL-22 (interleukin-22) signaling. Conversely, cholesterol reduction mediated by intestinal cholesterol excretion was blocked by inhibition of MAIT cells. Moreover, MAIT cell-deficient MR1<sup>-/-</sup> Ldlr<sup>-/-</sup> mice exhibited elevated total cholesterol levels and increased atherosclerotic lesions. In patients with hypercholesterolemia, circulating MAIT cell frequency displayed negative correlations with VLDL-C levels and positive correlations with HDL-C (high-density lipoprotein cholesterol) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings demonstrate a new mechanism for plasma VLDL-C clearance by MAIT cell-mediated cholesterol excretion. The results provide further evidence that immunity is involved in cholesterol homeostasis. Targeting intestinal immunity to regulate cholesterol homeostasis holds promise as a new cholesterol-lowering modality to prevent atherosclerotic cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40135347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40135347</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325841>10.1161/CIRCRESAHA.124.325841</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40135347</guid>
<pubDate>Wed, 26 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Hua Wang</dc:creator>
<dc:creator>Pukar K C</dc:creator>
<dc:creator>Kaidi Zhang</dc:creator>
<dc:creator>Clément Materne</dc:creator>
<dc:creator>Marie Lhomme</dc:creator>
<dc:creator>Sophie Galier</dc:creator>
<dc:creator>Farid Ichou</dc:creator>
<dc:creator>Carolina Neves</dc:creator>
<dc:creator>Agnes Lehuen</dc:creator>
<dc:creator>Joel T Haas</dc:creator>
<dc:creator>Joe-Elie Salem</dc:creator>
<dc:creator>Maryse Guerin</dc:creator>
<dc:creator>Philippe Lesnik</dc:creator>
<dc:date>2025-03-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>MAIT Cells Promote Cholesterol Excretion Pathways Mitigating Atherosclerosis</dc:title>
<dc:identifier>pmid:40135347</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325841</dc:identifier>
</item>
<item>
<title>Functional and antigenic landscape of the Nipah virus receptor-binding protein</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40132580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250327161224&amp;v=2.18.0.post9+e462414
      <description>Nipah virus recurrently spills over to humans, causing fatal infections. The viral receptor-binding protein (RBP or G) attaches to host receptors and is a major target of neutralizing antibodies. Here, we use deep mutational scanning to measure how all amino-acid mutations to the RBP affect cell entry, receptor binding, and escape from neutralizing antibodies. We identify functionally constrained regions of the RBP, including sites involved in oligomerization, along with mutations that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 20:S0092-8674(25)00257-0. doi: 10.1016/j.cell.2025.02.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nipah virus recurrently spills over to humans, causing fatal infections. The viral receptor-binding protein (RBP or G) attaches to host receptors and is a major target of neutralizing antibodies. Here, we use deep mutational scanning to measure how all amino-acid mutations to the RBP affect cell entry, receptor binding, and escape from neutralizing antibodies. We identify functionally constrained regions of the RBP, including sites involved in oligomerization, along with mutations that differentially modulate RBP binding to its two ephrin receptors. We map escape mutations for six anti-RBP antibodies and find that few antigenic mutations are present in natural Nipah strains. Our findings offer insights into the potential for functional and antigenic evolution of the RBP that can inform the development of antibody therapies and vaccines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40132580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250327161224&v=2.18.0.post9+e462414">40132580</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.030>10.1016/j.cell.2025.02.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40132580</guid>
<pubDate>Tue, 25 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Brendan B Larsen</dc:creator>
<dc:creator>Teagan McMahon</dc:creator>
<dc:creator>Jack T Brown</dc:creator>
<dc:creator>Zhaoqian Wang</dc:creator>
<dc:creator>Caelan E Radford</dc:creator>
<dc:creator>James E Crowe</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:creator>Jesse D Bloom</dc:creator>
<dc:date>2025-03-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Functional and antigenic landscape of the Nipah virus receptor-binding protein</dc:title>
<dc:identifier>pmid:40132580</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.030</dc:identifier>
</item>





























</channel>
</rss>